Synlogic (SYBX) Competitors $1.14 -0.02 (-2.07%) As of 04/25/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. ONCY, VRCA, VNRX, PMVP, ICCC, STRO, PDSB, CUE, CTMX, and MDCXShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Oncolytics Biotech (ONCY), Verrica Pharmaceuticals (VRCA), VolitionRx (VNRX), PMV Pharmaceuticals (PMVP), ImmuCell (ICCC), Sutro Biopharma (STRO), PDS Biotechnology (PDSB), Cue Biopharma (CUE), CytomX Therapeutics (CTMX), and Medicus Pharma (MDCX). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Oncolytics Biotech Verrica Pharmaceuticals VolitionRx PMV Pharmaceuticals ImmuCell Sutro Biopharma PDS Biotechnology Cue Biopharma CytomX Therapeutics Medicus Pharma Synlogic (NASDAQ:SYBX) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations. Is SYBX or ONCY more profitable? Oncolytics Biotech's return on equity of -141.15% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -207.84% -114.81% Oncolytics Biotech N/A -141.15%-84.73% Which has preferable earnings & valuation, SYBX or ONCY? Oncolytics Biotech has lower revenue, but higher earnings than Synlogic. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$8K1,666.68-$57.28M-$2.51-0.45Oncolytics BiotechN/AN/A-$20.56M-$0.30-1.85 Does the MarketBeat Community prefer SYBX or ONCY? Synlogic received 171 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 69.54% of users gave Synlogic an outperform vote while only 68.67% of users gave Oncolytics Biotech an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% Oncolytics BiotechOutperform Votes16068.67% Underperform Votes7331.33% Do institutionals and insiders hold more shares of SYBX or ONCY? 63.4% of Synlogic shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 3.0% of Synlogic shares are owned by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate SYBX or ONCY? Oncolytics Biotech has a consensus price target of $4.33, indicating a potential upside of 679.10%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Oncolytics Biotech is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, SYBX or ONCY? Synlogic has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Does the media prefer SYBX or ONCY? In the previous week, Oncolytics Biotech had 1 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Oncolytics Biotech and 1 mentions for Synlogic. Synlogic's average media sentiment score of 1.89 beat Oncolytics Biotech's score of 0.93 indicating that Synlogic is being referred to more favorably in the media. Company Overall Sentiment Synlogic Very Positive Oncolytics Biotech Positive SummaryOncolytics Biotech beats Synlogic on 9 of the 16 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.33M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E Ratio-0.277.1422.1418.40Price / Sales1,666.68238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.256.266.664.18Net Income-$57.28M$142.48M$3.21B$247.71M7 Day Performance7.55%7.90%6.16%6.56%1 Month Performance-12.91%-4.23%-2.86%-2.25%1 Year Performance-39.04%-2.70%16.43%4.67% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic2.1353 of 5 stars$1.14-1.7%N/A-39.7%$13.33M$8,000.00-0.2780Positive NewsGap DownONCYOncolytics Biotech1.5856 of 5 stars$0.59-5.3%$4.33+634.5%-48.5%$50.99MN/A-2.1930News CoverageVRCAVerrica Pharmaceuticals3.3634 of 5 stars$0.55+14.2%$9.50+1,618.2%-92.6%$50.75M$7.57M-0.3040Positive NewsVNRXVolitionRx1.6359 of 5 stars$0.50+2.9%$3.33+563.7%-45.3%$50.60M$1.23M-1.3980PMVPPMV Pharmaceuticals2.2054 of 5 stars$0.95+9.2%$5.67+495.2%-39.2%$49.44MN/A-0.9550News CoverageICCCImmuCell0.5141 of 5 stars$5.50+1.7%N/A+7.8%$49.41M$26.49M-11.0070High Trading VolumeSTROSutro Biopharma4.188 of 5 stars$0.60-0.9%$6.63+1,009.9%-73.6%$49.22M$62.04M-0.37240News CoverageGap DownPDSBPDS Biotechnology1.7164 of 5 stars$1.08+4.9%$9.00+733.3%-61.7%$49.03MN/A-0.9320Analyst RevisionNews CoveragePositive NewsGap DownCUECue Biopharma4.374 of 5 stars$0.79+3.3%$3.00+279.3%-44.3%$48.90M$9.29M-0.8860Positive NewsCTMXCytomX Therapeutics3.954 of 5 stars$0.61+13.8%$4.77+687.4%-55.6%$48.55M$138.10M3.57170News CoverageMDCXMedicus PharmaN/A$3.61+0.8%$12.00+232.4%N/A$48.43MN/A0.00N/AGap Up Related Companies and Tools Related Companies Oncolytics Biotech Competitors Verrica Pharmaceuticals Competitors VolitionRx Competitors PMV Pharmaceuticals Competitors ImmuCell Competitors Sutro Biopharma Competitors PDS Biotechnology Competitors Cue Biopharma Competitors CytomX Therapeutics Competitors Medicus Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SYBX Stock Free SYBX Stock Alerts